Precision Breast Cancer Trial Shows Improved Treatment by Tumor Subtype
University of California, San Francisco (UCSF)Recent results from one of the I-SPY 2.2 study arms, published September 14, 2024 in Nature Medicine, showed that neoadjuvant treatment with the antibody-drug conjugate datopotamab鈥揹eruxtecan (Dato-DXd) in combination with the immune checkpoint inhibitor, durvalumab (Imfinzi), produced high rates of pCR in patients who have an immune breast cancer subtype as well as a subtype of triple negative cancer that would ordinarily have a high risk of recurrence.